Overview

Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a 2-part, open label, fixed-sequence study to evaluate the potential drug interaction between ALXN2050 and fluconazole (Part 1), and between ALXN2050 and rifampin (Part 2) in healthy adult participants. Part 1 will be a 2-period, fixed-sequence study. Part 2 will be a single-period, fixed-sequence study.
Phase:
Phase 1
Details
Lead Sponsor:
Alexion Pharmaceuticals
Treatments:
Fluconazole
Rifampin